We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Industry Insights

A Vaccine for Alzheimer’s Disease? An Interview With AC Immune’s Prof Andrea Pfeifer
Industry Insight

Swiss biopharma AC Immune has made targeting Alzheimer’s disease, the leading form of dementia, a top priority. 2020 has brought mixed news for AC Immune's therapeutics, including promising safety data for their anti-Alzheimer's disease vaccine candidate. To discuss AC Immune’s work, Technology Networks spoke to CEO Prof. Andrea Pfeifer.

Read More

Could DMT-Assisted Therapy Help Treat Mental Health Disorders?
Industry Insight

The role that psychedelic therapeutics could play in tackling many intractable mental health conditions has finally been recognized by mainstream medicine. To find out more, we spoke to Carol Routledge, Chief Medical & Scientific Officer at Small Pharma.

Read More

Ensuring Data Integrity Compliance in Pharma With CDS Software
Industry Insight

Data integrity is fundamental to drug development and manufacturing but can be difficult to achieve for drug developers and manufacturers who have to navigate strict data integrity guidelines provided by regulatory authorities and find effective ways to attain compliance.

Read More

Cell and Gene Therapy Manufacturing: Achieving Consistency and Reducing Variability
Industry Insight

Cell and gene therapies first gained regulatory approval in 2017 by the US Food and Drug Administration (FDA). Several more therapies have since been developed, and there are now 18 approved to treat a variety of diseases Technology Networks recently had the pleasure of speaking with experts at Bio-Techne to learn more about the cell and gene therapy manufacturing process.

Read More

Addressing Key Challenges in Cell and Gene Therapy Manufacturing
Industry Insight

Technology Networks spoke with Hugh H. Tansey, senior director of innovation and growth programs for laboratory equipment at Thermo Fisher Scientific to learn more about how the CTS Series Laboratory Equipment can deliver solutions for the key challenges in cell and gene therapy manufacturing.

Read More

Leading the Charge in the Cryo-EM Resolution Revolution
Industry Insight

See how cryo-EM advances are changing scientific research, particularly in cell and drug discovery studies, and the role that precision instruments are playing in this.

Read More

Accelerated Screen Identifies 25 Existing Drugs Capable of Disrupting SARS-CoV-2 Cell Entry
Industry Insight

A team from the National Center for Advancing Translational Sciences (NCATS) has screened existing drug compounds that have already passed through the entire drug development pipeline, to determine if any can disrupt the interaction between the SARS-CoV-2 spike protein and the host’s angiotensin converting enzyme 2 (ACE2) receptor.

Read More

Advanced Cell Screening and Imaging Reveals How the Cardiac System Responds in Drug Development
Industry Insight

In drug discovery, time and monetary investments increase significantly the further candidates advance through the preclinical phase of testing, analysis and evaluation. By excluding non-viable compounds for safety and toxicity reasons early on, resources can be redirected to bring the most promising drugs to market sooner.

Read More

Looking Beyond the Spike Protein for SARS-CoV-2 Vaccine Design
Industry Insight

Biotech company COVAXX is developing a COVID-19 vaccine using a multi-antigen peptide platform, which not only targets the infamous SARS-CoV-2 Spike (S) protein but also targets other parts of the virus to enhance the immune response. Technology Networks spoke with Mei Mei Hu, co-founder of COVAXX, to learn more about the vaccine platform and the preclinical data that has been obtained for UB-612.

Read More

Antiviral Conjugates – A Novel Treatment and Prevention Strategy for Viral Diseases Including COVID-19
Industry Insight

Infectious diseases remain a major health threat. The ongoing evolution of viral variants makes it likely that emerging infections will continue to occur – highlighting the need to develop new therapeutic and preventive approaches. Jeff Stein, PhD, President and CEO at Cidara Therapeutics tells Technology Networks more about a novel antiviral strategy they have developed called antiviral conjugates.

Read More

 
Advertisement